News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PhytoMedical Technologies, Inc. (PYTO.OB) Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization Medicilon-MPI Preclinical Research (Shanghai) LLC to Advance Brain Cancer Drug Candidate



4/15/2010 9:08:53 AM

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of ‘D11B’, an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES